Photodynamic therapy (PDT) has been widely used in preclinical trials for treating various tumors. However, the hypoxic environment of tumors and the limited penetration depth of ultraviolet light severely weaken the PDT effect. To solve the above problems, a near-infrared (NIR) light-triggered oxygen (O 2 ) self-supplied phototherapeutic platform (UCNPs/CeO 2 /Ce6/BSA) for amplified PDT performance against solid tumors by alleviating tumor hypoxia has been rationally developed. The platform has excellent stability and can continuously decompose H 2 O 2 for sustained O 2 supply to synergize 1 O 2 generation, thus inducing an enhanced mortality rate (59%) of ID8 cells in vitro under hypoxic + H 2 O 2 conditions. The growth of solid tumors was effectively inhibited and the mouse survival rate was dramatically enhanced via a superior PDT therapeutic performance. This reported study facilitated the positive development of multifunctional diagnosis and treatment platforms under long-wavelength excitation for O 2 self-supplied tumor treatments.
Keyphrases
- photodynamic therapy
- fluorescence imaging
- induced apoptosis
- high throughput
- mental health
- drug delivery
- cell cycle arrest
- cardiovascular events
- optical coherence tomography
- energy transfer
- endothelial cells
- stem cells
- type diabetes
- risk factors
- cancer therapy
- oxidative stress
- endoplasmic reticulum stress
- cell death
- signaling pathway
- single cell
- bone marrow
- cell proliferation